Moderna expanding to Marlborough, investing $322M in biomanufacturing facility
Photo | Courtesy of JLL
Moderna has purchased a new Marlborough biomanufacturing facility.
Cambridge-based drug manufacturer Moderna, Inc. has purchased a 140,000-square-foot biomanufacturing facility at 149 Hayes Memorial Drive in Marlborough.
Moderna will build out the facility, anticipating it will complete construction in June 2024 with an anticipated opening in September 2024, according to a tax-increment financing application submitted to the Marlborough City Council on April 20. The project will add 60,000 square feet to the maximum build out and is expected to cost more than $322 million.
The facility will house office and mRNA manufacturing space. The buildout will include a full manufacturing clean room environment, quality control lab space, a just-in-time satellite warehouse and offices, according to the application.
The company indicated its intention to maintain a minimum of 200 permanent full-time jobs by 2026 at the facility, according to the application, which was first reported on by Community Advocate.
Moderna requested a 20-year tax exemption in which it would pay no real property taxes until fiscal 2028 with the rate of exemption gradually decreasing over time. The TIF will be reviewed by the Marlborough City Council Finance Committee at its Monday meeting, according to Executive Director Meredith Harris of the Marlborough Economic Development Corp.
The facility at 149 Hayes was developed by Toronto-based Oxford Properties Group in partnership with The Gutierrez Co. of Burlington. The $91-million property sale was completed on Thursday, according to the Middlesex South Registry of Deeds. National real estate firm JLL, which has a Boston office, represented the seller in the transaction. The undeveloped property was purchased by the developers in September 2021.
Moderna is a biotechnology and pharmaceutical firm specializing in mRNA technology. It was one of the two main companies that created and distributed a COVID-19 vaccine during the pandemic. The company employs 3,900 people worldwide and has Massachusetts locations in Cambridge, Norwood, and Burlington.
The company has 48 products in the development pipeline. In addition to infectious disease vaccines, Moderna is using its technology to research cancer treatments, cardiovascular diseases, and autoimmune diseases.
WBJ Web Partners
Most Recent
Most Recent
0 Comments